Cell biological factors associated with the response of breast cancer to systemic treatment.

[1]  J. Coindre,et al.  Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas a , 1993, Annals of the New York Academy of Sciences.

[2]  J. Foekens,et al.  Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. , 1993, British Journal of Cancer.

[3]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Foekens,et al.  Critical review of growth factors as clinical tools in primary and metastatic breast cancer. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[5]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[6]  J. Foekens,et al.  Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.

[7]  E. Krenning,et al.  Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  J. Foekens,et al.  Clinical breast cancer, new developments in selection and endocrine treatment of patients , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  T. Pandita,et al.  Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. , 1992, Cancer research.

[10]  J. Foekens,et al.  Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Umberto Veronesi,et al.  Breast cancer (Third of three parts) , 1992 .

[12]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Andrulis,et al.  The HER-2/neu oncogene in breast cancer: so what is new? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. McGuire,et al.  Response of human breast cancer cells to heat shock and chemotherapeutic drugs. , 1992, Cancer research.

[16]  J. Sparano,et al.  The potential role for biological therapy in the treatment of breast cancer. , 1992, Seminars in oncology.

[17]  M. Lynch,et al.  Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. , 1992, British Journal of Cancer.

[18]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[20]  J. Foekens,et al.  Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. , 1992, Cancer research.

[21]  J. Foekens,et al.  Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.

[22]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[23]  J. Cairns,et al.  Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. , 1992, British Journal of Cancer.

[24]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[25]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[26]  D. Hayes,et al.  Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K J Cullen,et al.  Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. , 1992, Molecular endocrinology.

[28]  A. Harris,et al.  Mechanisms of multidrug resistance in cancer treatment. , 1992, Acta oncologica.

[29]  H. Rochefort,et al.  Cathepsin D in breast cancer: a tissue marker associated with metastasis. , 1992, European journal of cancer.

[30]  R. Clarke,et al.  Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. , 1992, Critical reviews in oncology/hematology.

[31]  S. Romain,et al.  c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. , 1992, European journal of cancer.

[32]  K. Pritchard,et al.  Adjuvant endocrine therapy of breast cancer. , 1992, Cancer treatment and research.

[33]  V. Jordan,et al.  Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target. , 1992, Seminars in oncology.

[34]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[35]  R. Dickson,et al.  Tissue culture conditions determine the effects of estrogen and growth factors on the anchorage independent growth of human breast cancer cell lines , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  B. Katzenellenbogen.  Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. , 1991, Journal of the National Cancer Institute.

[37]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[38]  T. Kwok,et al.  Epidermal growth factor reduces resistance to doxorubicin , 1991, International journal of cancer.

[39]  M. Millward,et al.  Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer , 1991, The Lancet.

[40]  N. Piggott,et al.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. , 1991, British Journal of Cancer.

[41]  J. Bártková,et al.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.

[42]  T. Perren.  c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.

[43]  P. Chambon,et al.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer. , 1991, Cancer research.

[44]  M. Fernö,et al.  Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. , 1991, British Journal of Cancer.

[45]  J. Foekens,et al.  Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  J. Bonneterre,et al.  Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  J. Klijn,et al.  Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group , 1990, Journal of Steroid Biochemistry and Molecular Biology.

[48]  J. Foekens,et al.  Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  C. Osborne,et al.  Regulation of breast cancer growth by insulin-like growth factors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  A. Harris,et al.  Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[52]  R Beuscart,et al.  Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. , 1990, Cancer research.

[53]  J. Foekens,et al.  Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors , 1990, International journal of cancer.

[54]  D. Slamon,et al.  UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer. , 1990, Cancer research.

[55]  J. Foekens,et al.  Prediction of relapse and survival in breast cancer patients by pS2 protein status. , 1990, Cancer research.

[56]  P. Rabbitts,et al.  Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. , 1990, British Journal of Cancer.

[57]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[58]  W. Gullick.  New developments in the molecular biology of breast cancer. , 1990, European journal of cancer.

[59]  J. Klijn,et al.  The clinical use of somatostatin analogues in the treatment of cancer. , 1990, Bailliere's clinical endocrinology and metabolism.

[60]  A. Harris.  Epidermal growth factor receptor: A marker of early relapse in breast cancer: Interactions with NEU , 1990 .

[61]  J. Henry,et al.  Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. , 1990, British Journal of Cancer.

[62]  P. Darbre.  6. Steroids and steroid receptors in growth control of cultured breast cancer cells , 1990 .

[63]  J. Foekens,et al.  Prognostic Factors in Breast Cancer , 1990 .

[64]  D. Merkel,et al.  Prognostic factors in breast cancer. , 1992, The New England journal of medicine.

[65]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[66]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[67]  J. Foekens,et al.  Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. , 1989, Endocrinology.

[68]  R. Coombes,et al.  Characterisation of a messenger RNA selectively expressed in human breast cancer. , 1989, British Journal of Cancer.

[69]  J. Foekens,et al.  Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer , 1989, Cancer.

[70]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[71]  J. Klijn,et al.  Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.

[72]  R Clarke,et al.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Devlin,et al.  Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. , 1989, Cancer research.

[74]  C K Osborne,et al.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.

[75]  E. Szabo,et al.  Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. , 1989, Cancer research.

[76]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[77]  A. Schally,et al.  Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer , 1989, Journal of clinical laboratory analysis.

[78]  J. Bonneterre,et al.  Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. , 1988, Cancer Research.

[79]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[80]  J. Foekens,et al.  Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). , 1988, European journal of cancer & clinical oncology.

[81]  E. Rutanen,et al.  Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. , 1988, Cancer research.

[82]  J. Klijn,et al.  The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.

[83]  L. Rutqvist,et al.  Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen. , 1987, Cancer treatment reports.

[84]  C. Osborne,et al.  Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. , 1987, European journal of cancer & clinical oncology.

[85]  R. Camplejohn,et al.  Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. , 1987, British Journal of Cancer.

[86]  J. Foekens,et al.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.

[87]  A. Howell,et al.  Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. , 1987, Cancer research.

[88]  A. Howell,et al.  MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER , 1986, The Lancet.

[89]  B. Spengler,et al.  Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Klijn,et al.  Chemotherapy with estrogenic recruitment in breast cancer: experimental and clinical studies. , 1985 .

[91]  K. Horwitz,et al.  Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.

[92]  H. Portengen,et al.  Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. , 1980, Cancer research.

[93]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.